Perparim Limani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Perparim Limani has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
- Rolf Graf
Department of Visceral and Transplantation Surgery, University Hospital Zurich, Switzerland
14 shared publications - Pierre-Alain Clavien
Department of Surgery and Transplantation, University of Zurich, Zurich, Switzerland
11 shared publications - Jean-Marie Lehn
Laboratoire De Chimie Supramoléculaire Institut De Science et D'ingénierie Supramoléculaires (ISIS) Université De Strasbourg Strasbourg France
6 shared publications - Michael Linecker
Department of Surgery and Transplantation, Swiss HPB and Transplant Center, University Hospital Zurich, Zurich, Switzerland
6 shared publications Bostjan Humar
Swiss Hepato-Pancreato-Biliary (HPB) and Transplantation Center, University Hospital Zurich, Zurich, Switzerland
5 shared publications- Bostjan Humar
Department of Surgery, Swiss Hepato-Pancreato-Biliary and Transplantation Center, University Hospital Zürich, Zürich, Switzerland
5 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
ITPP in early pancreatic zebrafish xenografts mildly impacts tumor cell death without interfering with vascular normalization
Myo-inositol trispyrophosphate (ITPP) is an anti-hypoxic small molecule that acts as an allosteric effector of hemoglobin in erythrocytes. To capture the e
- 7 May 2026
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open AccessITPP in early pancreatic zebrafish xenografts mildly impacts tumor cell death without interfering with vascular normalization
Myo-inositol trispyrophosphate (ITPP) is an anti-hypoxic small molecule that acts as an allosteric effector of hemoglobin in erythrocytes. To capture the e
- Open Access
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3873
Hypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy
Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, with a 5-year survival rate of 13% and broad resistance to therapy. It is driven by severe tumor hypoxia from desmoplasia, aberrant vasculature, and high interstitial pressure. Hypoxia stabilizes hypoxia-inducible factors (HIFs), reshaping the tumor microenvironment (TME) into a nutrient-poor, acidic milieu that fosters immune exclusion and suppression. While immune checkpoint inhibitors (ICIs) have revolutionized treatment, PDAC responses have been negligible. As hypoxia centrally drives PDAC’s ICI-refractory TME, targeted alleviation could offer synergy with ICIs; however, no such combination is being applied in the clinic. One impediment could be the one-size-fits-all approach when investigating hypoxia-modifying therapy. Indeed, using hypoxia gene signatures, we and others have shown that PDAC tumors are not equally hypoxic, with patients having more hypoxic tumors experiencing worse survival and immunosuppressed TME. This review dissects hypoxia’s mechanistic role in PDAC immune evasion and gives an update on the therapeutic advances that directly or indirectly target hypoxia, such as the inhibition of HIFs, hypoxia-activated prodrugs, and vascular and oxygen delivery approaches, with emphasis on their potential to enhance responses to ICIs. It further evaluates the need for hypoxia biomarkers and proposes gene signatures as detection tools to enable precision hypoxia modulation, potentially converting immune-cold PDAC into an ICI-responsive disease.
- 27 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3873
Open AccessHypoxic Tumor Microenvironment Targeting: Opportunities and Challenges for Pancreatic Cancer Immunotherapy
Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest cancers, with a 5-year survival rate of 13% and broad resistance to therapy. It is driven by severe tumor hypoxia from desmoplasia, aberrant vasculature, and high interstitial pressure. Hypoxia stabilizes hypoxia-inducible factors (HIFs), reshaping the tumor microenvironment (TME) into a nutrient-poor, acidic milieu that fosters immune exclusion and suppression. While immune checkpoint inhibitors (ICIs) have revolutionized treatment, PDAC responses have been negligible. As hypoxia centrally drives PDAC’s ICI-refractory TME, targeted alleviation could offer synergy with ICIs; however, no such combination is being applied in the clinic. One impediment could be the one-size-fits-all approach when investigating hypoxia-modifying therapy. Indeed, using hypoxia gene signatures, we and others have shown that PDAC tumors are not equally hypoxic, with patients having more hypoxic tumors experiencing worse survival and immunosuppressed TME. This review dissects hypoxia’s mechanistic role in PDAC immune evasion and gives an update on the therapeutic advances that directly or indirectly target hypoxia, such as the inhibition of HIFs, hypoxia-activated prodrugs, and vascular and oxygen delivery approaches, with emphasis on their potential to enhance responses to ICIs. It further evaluates the need for hypoxia biomarkers and proposes gene signatures as detection tools to enable precision hypoxia modulation, potentially converting immune-cold PDAC into an ICI-responsive disease.
- Open Access
- 24 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7555
Toward Artificial Intelligence in Oncology and Cardiology: A Narrative Review of Systems, Challenges, and Opportunities
Background: Artificial intelligence (AI), the overarching field that includes machine learning (ML) and its subfield deep learning (DL), is rapidly transforming clinical research by enabling the analysis of high-dimensional data and automating the output of diagnostic and prognostic tests. As clinical trials become increasingly complex and costly, ML-based approaches (especially DL for image and signal data) offer promising solutions, although they require new approaches in clinical education. Objective: Explore current and emerging AI applications in oncology and cardiology, highlight real-world use cases, and discuss the challenges and future directions for responsible AI adoption. Methods: This narrative review summarizes various aspects of AI technology in clinical research, exploring its promise, use cases, and its limitations. The review was based on a literature search in PubMed covering publications from 2019 to 2025. Search terms included “artificial intelligence”, “machine learning”, “deep learning”, “oncology”, “cardiology”, “digital twin”. and “AI-ECG”. Preference was given to studies presenting validated or clinically applicable AI tools, while non-English articles, conference abstracts, and gray literature were excluded. Results: AI demonstrates significant potential in improving diagnostic accuracy, facilitating biomarker discovery, and detecting disease at an early stage. In clinical trials, AI improves patient stratification, site selection, and virtual simulations via digital twins. However, there are still challenges in harmonizing data, validating models, cross-disciplinary training, ensuring fairness, explainability, as well as the robustness of gold standards to which AI models are built. Conclusions: The integration of AI in clinical research can enhance efficiency, reduce costs, and facilitate clinical research as well as lead the way towards personalized medicine. Realizing this potential requires robust validation frameworks, transparent model interpretability, and collaborative efforts among clinicians, data scientists, and regulators. Interoperable data systems and cross-disciplinary education will be critical to enabling the integration of scalable, ethical, and trustworthy AI into healthcare.
- 24 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7555
Open AccessToward Artificial Intelligence in Oncology and Cardiology: A Narrative Review of Systems, Challenges, and Opportunities
Background: Artificial intelligence (AI), the overarching field that includes machine learning (ML) and its subfield deep learning (DL), is rapidly transforming clinical research by enabling the analysis of high-dimensional data and automating the output of diagnostic and prognostic tests. As clinical trials become increasingly complex and costly, ML-based approaches (especially DL for image and signal data) offer promising solutions, although they require new approaches in clinical education. Objective: Explore current and emerging AI applications in oncology and cardiology, highlight real-world use cases, and discuss the challenges and future directions for responsible AI adoption. Methods: This narrative review summarizes various aspects of AI technology in clinical research, exploring its promise, use cases, and its limitations. The review was based on a literature search in PubMed covering publications from 2019 to 2025. Search terms included “artificial intelligence”, “machine learning”, “deep learning”, “oncology”, “cardiology”, “digital twin”. and “AI-ECG”. Preference was given to studies presenting validated or clinically applicable AI tools, while non-English articles, conference abstracts, and gray literature were excluded. Results: AI demonstrates significant potential in improving diagnostic accuracy, facilitating biomarker discovery, and detecting disease at an early stage. In clinical trials, AI improves patient stratification, site selection, and virtual simulations via digital twins. However, there are still challenges in harmonizing data, validating models, cross-disciplinary training, ensuring fairness, explainability, as well as the robustness of gold standards to which AI models are built. Conclusions: The integration of AI in clinical research can enhance efficiency, reduce costs, and facilitate clinical research as well as lead the way towards personalized medicine. Realizing this potential requires robust validation frameworks, transparent model interpretability, and collaborative efforts among clinicians, data scientists, and regulators. Interoperable data systems and cross-disciplinary education will be critical to enabling the integration of scalable, ethical, and trustworthy AI into healthcare.
- Open Access
- 17 May 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (11) , 3465-3466
Distinct [18F]FDG-PET imaging features of a newly recognized and yet uncharacterized RDD-ECD overlap disease entity
- 17 May 2024
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 51 (11) , 3465-3466
Open AccessDistinct [18F]FDG-PET imaging features of a newly recognized and yet uncharacterized RDD-ECD overlap disease entity
- 28 November 2023
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 97, 104-123
Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy
- 28 November 2023
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 97, 104-123
Hypoxia as a potential inducer of immune tolerance, tumor plasticity and a driver of tumor mutational burden: Impact on cancer immunotherapy
- Open Access
- 30 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4428
The Role of Pancreatic Stone Protein (PSP) as a Biomarker of Pregnancy-Related Diseases
Background: Pancreatic stone protein (PSP) is a biochemical serum marker that contains levels that are elevated in various inflammatory and infectious diseases. The role of PSP in the diagnosis of these diseases seems to be more important compared to clinically established biochemical serum markers in discriminating the severity of the same diseases. Standard values for PSP in pregnant women in relation to gestational age have been reported recently. Additionally, increased PSP levels have been observed to be associated with renal dysfunction in pregnant women. The aim of this study is to evaluate the diagnostic role of PSP in pregnancy-related diseases, such as pre-eclampsia (PE), hemolysis-elevated liver enzymes, and low platelet (HELLP) syndrome. In addition, the study aims to assess its diagnostic role in inflammation-triggered diseases as preterm premature rupture of membranes (PPROM) or COVID-19-positive pregnant women. Materials and Methods: In this single-centred prospective study performed at a tertiary university hospital between 2013 and 2021, we included 152 pregnant women who were diagnosed with either PE, HELLP syndrome, or PPROM. In December 2020, in the context of the COVID-19 pandemic, the Independent Ethics Committee (IEC) approved an amendment to the study protocol. Depending on the underlying disease, single or serial-serum PSP measurements were assessed. These PSP values were compared to PSP levels of women with normal pregnancies. Results: Pregnant women diagnosed with pre-eclampsia or HELLP syndrome had significantly increased PSP values (mean 9.8 ng/mL, SD 2.6) compared to healthy singleton pregnant women (mean 7.9 ng/mL, SD 2.6, p ≤ 0.001). There was no difference in serum PSP in pregnant women with PPROM compared to women with uncomplicated singleton pregnancies (mean in PPROM: 7.9 ng/mL; SD 2.9 versus mean in healthy pregnancies: 7.9 ng/mL; SD 2.6, p = 0.98). Furthermore, no difference in the PSP values in women with or without intra-amniotic infection was observed (infection: mean 7.9 ng/mL; SD 2.8 versus no infection: mean 7.8 ng/mL; SD 3, p = 0.85). The mean value of PSP in COVID-19-infected women during pregnancy (8.5 ng/mL, SD 2.3) was comparable to healthy singleton pregnancies (mean 7.9 ng/mL, SD 2.6), p = 0.24. Conclusions: The novel serum biomarker PSP is significantly upregulated in pregnant women with pre-eclampsia and HELLP syndrome. Our observations call for the further evaluation of PSP in randomized controlled clinical trials to demonstrate the actual role of PSP in pregnancy-related diseases and whether it may provide new approaches for the management and discrimination of the severity of these gestational conditions.
- 30 June 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (13) , 4428
Open AccessThe Role of Pancreatic Stone Protein (PSP) as a Biomarker of Pregnancy-Related Diseases
Background: Pancreatic stone protein (PSP) is a biochemical serum marker that contains levels that are elevated in various inflammatory and infectious diseases. The role of PSP in the diagnosis of these diseases seems to be more important compared to clinically established biochemical serum markers in discriminating the severity of the same diseases. Standard values for PSP in pregnant women in relation to gestational age have been reported recently. Additionally, increased PSP levels have been observed to be associated with renal dysfunction in pregnant women. The aim of this study is to evaluate the diagnostic role of PSP in pregnancy-related diseases, such as pre-eclampsia (PE), hemolysis-elevated liver enzymes, and low platelet (HELLP) syndrome. In addition, the study aims to assess its diagnostic role in inflammation-triggered diseases as preterm premature rupture of membranes (PPROM) or COVID-19-positive pregnant women. Materials and Methods: In this single-centred prospective study performed at a tertiary university hospital between 2013 and 2021, we included 152 pregnant women who were diagnosed with either PE, HELLP syndrome, or PPROM. In December 2020, in the context of the COVID-19 pandemic, the Independent Ethics Committee (IEC) approved an amendment to the study protocol. Depending on the underlying disease, single or serial-serum PSP measurements were assessed. These PSP values were compared to PSP levels of women with normal pregnancies. Results: Pregnant women diagnosed with pre-eclampsia or HELLP syndrome had significantly increased PSP values (mean 9.8 ng/mL, SD 2.6) compared to healthy singleton pregnant women (mean 7.9 ng/mL, SD 2.6, p ≤ 0.001). There was no difference in serum PSP in pregnant women with PPROM compared to women with uncomplicated singleton pregnancies (mean in PPROM: 7.9 ng/mL; SD 2.9 versus mean in healthy pregnancies: 7.9 ng/mL; SD 2.6, p = 0.98). Furthermore, no difference in the PSP values in women with or without intra-amniotic infection was observed (infection: mean 7.9 ng/mL; SD 2.8 versus no infection: mean 7.8 ng/mL; SD 3, p = 0.85). The mean value of PSP in COVID-19-infected women during pregnancy (8.5 ng/mL, SD 2.3) was comparable to healthy singleton pregnancies (mean 7.9 ng/mL, SD 2.6), p = 0.24. Conclusions: The novel serum biomarker PSP is significantly upregulated in pregnant women with pre-eclampsia and HELLP syndrome. Our observations call for the further evaluation of PSP in randomized controlled clinical trials to demonstrate the actual role of PSP in pregnancy-related diseases and whether it may provide new approaches for the management and discrimination of the severity of these gestational conditions.
- Open Access
- 29 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3200
Serum Pancreatic Stone Protein Reference Values in Healthy Pregnant Women: A Prospective Cohort Study
Background: In non-pregnant populations, pancreatic stone protein (PSP) has been reported to have a higher diagnostic performance for identifying severe inflammatory and infectious disease than other established biomarkers. Objective: To generate reference values for serum PSP in pregnancy and compare them to the values of the general healthy population. Design: A prospective cohort study. Setting: A single center. Population: Healthy women with singleton and multiple pregnancies. Methods: This is a prospective single-center cohort study. Between 2013 and 2021, samples of 5 mL peripheral blood were drawn from 440 healthy pregnant women. Therein, 393 cases were singletons and 47 were multiple pregnancies. Serum PSP levels were measured by specific enzyme-linked immunosorbent assay. The main outcome measures were serum PSP level (ng/mL) reference values in healthy pregnant women. Results: The mean PSP reference values in women with singleton pregnancies were 7.9 ± 2.6 ng/mL (95% CI; 2.69–13.03 ng/mL). The PSP values in women with multiple pregnancies (9.17 ± 3.06 ng/mL (95% CI; 3.05–15.28 ng/mL)) were significantly higher (p = 0.001). The PSP values in the first trimester (6.94 ± 2.53 ng/mL) were lower compared to the second (7.42 ± 2.21 ng/mL) and third trimesters (8.33 ± 2.68 ng/mL, p = 0.0001). Subgroup analyses in singletons revealed no correlations between PSP values, maternal characteristics, and pre-existing medical conditions. Conclusion: The PSP values in healthy pregnant women (4–12 ng/mL) were in the range of the reference values of the general healthy population (8–16 ng/mL). This insight blazes a trail for further clinical studies on the use of PSP as a potential novel biomarker for the early detection of pregnancy-related diseases such as chorioamnionitis.
- 29 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3200
Open AccessSerum Pancreatic Stone Protein Reference Values in Healthy Pregnant Women: A Prospective Cohort Study
Background: In non-pregnant populations, pancreatic stone protein (PSP) has been reported to have a higher diagnostic performance for identifying severe inflammatory and infectious disease than other established biomarkers. Objective: To generate reference values for serum PSP in pregnancy and compare them to the values of the general healthy population. Design: A prospective cohort study. Setting: A single center. Population: Healthy women with singleton and multiple pregnancies. Methods: This is a prospective single-center cohort study. Between 2013 and 2021, samples of 5 mL peripheral blood were drawn from 440 healthy pregnant women. Therein, 393 cases were singletons and 47 were multiple pregnancies. Serum PSP levels were measured by specific enzyme-linked immunosorbent assay. The main outcome measures were serum PSP level (ng/mL) reference values in healthy pregnant women. Results: The mean PSP reference values in women with singleton pregnancies were 7.9 ± 2.6 ng/mL (95% CI; 2.69–13.03 ng/mL). The PSP values in women with multiple pregnancies (9.17 ± 3.06 ng/mL (95% CI; 3.05–15.28 ng/mL)) were significantly higher (p = 0.001). The PSP values in the first trimester (6.94 ± 2.53 ng/mL) were lower compared to the second (7.42 ± 2.21 ng/mL) and third trimesters (8.33 ± 2.68 ng/mL, p = 0.0001). Subgroup analyses in singletons revealed no correlations between PSP values, maternal characteristics, and pre-existing medical conditions. Conclusion: The PSP values in healthy pregnant women (4–12 ng/mL) were in the range of the reference values of the general healthy population (8–16 ng/mL). This insight blazes a trail for further clinical studies on the use of PSP as a potential novel biomarker for the early detection of pregnancy-related diseases such as chorioamnionitis.
- Open Access
Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and it is a disease of dismal prognosis. While immunotherapy has revolutionized the treatment of various solid tumors, it has achieved little success in PDAC. Hypoxia within the stroma-rich tumor microenvironment is associated with resistance to therapies and promotes angiogenesis, giving rise to a chaotic and leaky vasculature that is inefficient at shuttling oxygen and nutrients. Hypoxia and its downstream effectors have been implicated in immune resistance and could be contributing to the lack of response to immunotherapy experienced by patients with PDAC. Paradoxically, increasing evidence has shown hypoxia to augment genomic instability and mutagenesis in cancer, suggesting that hypoxic tumor cells could have increased production of neoantigens that can potentially enable their clearance by cytotoxic immune cells. Strategies aimed at relieving this condition have been on the rise, and one such approach opts for normalizing the tumor vasculature to reverse hypoxia and its downstream support of tumor pathogenesis. An important consideration for the successful implementation of such strategies in the clinic is that not all PDACs are equally hypoxic, therefore hypoxia-detection approaches should be integrated to enable optimal patient selection for achieving improved patient outcomes.
Open AccessHypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, and it is a disease of dismal prognosis. While immunotherapy has revolutionized the treatment of various solid tumors, it has achieved little success in PDAC. Hypoxia within the stroma-rich tumor microenvironment is associated with resistance to therapies and promotes angiogenesis, giving rise to a chaotic and leaky vasculature that is inefficient at shuttling oxygen and nutrients. Hypoxia and its downstream effectors have been implicated in immune resistance and could be contributing to the lack of response to immunotherapy experienced by patients with PDAC. Paradoxically, increasing evidence has shown hypoxia to augment genomic instability and mutagenesis in cancer, suggesting that hypoxic tumor cells could have increased production of neoantigens that can potentially enable their clearance by cytotoxic immune cells. Strategies aimed at relieving this condition have been on the rise, and one such approach opts for normalizing the tumor vasculature to reverse hypoxia and its downstream support of tumor pathogenesis. An important consideration for the successful implementation of such strategies in the clinic is that not all PDACs are equally hypoxic, therefore hypoxia-detection approaches should be integrated to enable optimal patient selection for achieving improved patient outcomes.
- Open Access
- 19 May 2022
- Published by Springer Nature in Schweizer Gastroenterologie
- Vol. 3 (2) , 65-74
Multimodale Therapiekonzepte beim Rektumkarzinom
Zusammenfassung: Das kolorektale Karzinom (KRK) ist in der Schweiz das dritthäufigste Malignom bezüglich der Sterblichkeitsrate bei Männern und Frauen. Beim Kolonkarzinom ist weiterhin die primäre chirurgische Resektion der Goldstandard der Therapie. Beim Rektumkarzinom hingegen kommt ein differenziertes, stadienadaptiertes multimodales Therapiekonzept zur Anwendung. Frühe Tumoren (Stadium I + II ohne Lymphknotenbefall) können mit exzellenten Langzeitergebnissen alleinig chirurgisch behandelt werden. Fortgeschrittene Rektumkarzinome (Stadium III) im unteren und mittleren Rektumdrittel erfordern eine multimodale Therapie aus neoadjuvanter Behandlung (Radiotherapie, Radiochemotherapie, Chemotherapie), gefolgt von Resektion und ggf. adjuvanter Chemotherapie. Die totale neoadjuvante Therapie (TNT) erreicht durch Intensivierung der Vorbehandlung (sequenziell neoadjuvante Radio[chemo]therapie und neoadjuvante Chemotherapie) ein verbessertes Ansprechen und progressionsfreies Überleben. Nach komplettem Ansprechen auf neoadjuvante Therapie kann ein „Watch-and-wait-Konzept“ die chirurgische Resektion ersetzen. Dieser Übersichtsartikel befasst sich mit den aktuellen Standards der multimodalen Behandlungsschemata beim Rektumkarzinom.
- 19 May 2022
- Published by Springer Nature in Schweizer Gastroenterologie
- Vol. 3 (2) , 65-74
Open AccessMultimodale Therapiekonzepte beim Rektumkarzinom
Zusammenfassung: Das kolorektale Karzinom (KRK) ist in der Schweiz das dritthäufigste Malignom bezüglich der Sterblichkeitsrate bei Männern und Frauen. Beim Kolonkarzinom ist weiterhin die primäre chirurgische Resektion der Goldstandard der Therapie. Beim Rektumkarzinom hingegen kommt ein differenziertes, stadienadaptiertes multimodales Therapiekonzept zur Anwendung. Frühe Tumoren (Stadium I + II ohne Lymphknotenbefall) können mit exzellenten Langzeitergebnissen alleinig chirurgisch behandelt werden. Fortgeschrittene Rektumkarzinome (Stadium III) im unteren und mittleren Rektumdrittel erfordern eine multimodale Therapie aus neoadjuvanter Behandlung (Radiotherapie, Radiochemotherapie, Chemotherapie), gefolgt von Resektion und ggf. adjuvanter Chemotherapie. Die totale neoadjuvante Therapie (TNT) erreicht durch Intensivierung der Vorbehandlung (sequenziell neoadjuvante Radio[chemo]therapie und neoadjuvante Chemotherapie) ein verbessertes Ansprechen und progressionsfreies Überleben. Nach komplettem Ansprechen auf neoadjuvante Therapie kann ein „Watch-and-wait-Konzept“ die chirurgische Resektion ersetzen. Dieser Übersichtsartikel befasst sich mit den aktuellen Standards der multimodalen Behandlungsschemata beim Rektumkarzinom.
- Open Access
- 21 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound without apparent toxicity. In preclinical models, ITPP potentiates the efficacy of subsequent chemotherapy through vascular normalization. Here, we report the results of an unrandomized, open-labeled, 3 + 3 dose-escalation phase Ib study (NCT02528526) including 28 patients with advanced primary hepatopancreatobiliary malignancies and liver metastases of colorectal cancer receiving nine 8h-infusions of ITPP over three weeks across eight dose levels (1'866-14'500 mg/m2/dose), followed by standard chemotherapy. Primary objectives are assessment of the safety and tolerability and establishment of the maximum tolerated dose, while secondary objectives include assessment of pharmacokinetics, antitumor activity via radiological evaluation and assessment of circulatory tumor-specific and angiogenic markers. The maximum tolerated dose is 12,390 mg/m2, and ITPP treatment results in 32 treatment-related toxicities (mostly hypercalcemia) that require little or no intervention. 52% of patients have morphological disease stabilization under ITPP monotherapy. Following subsequent chemotherapy, 10% show partial responses while 60% have stable disease. Decreases in angiogenic markers are noted in ∼60% of patients after ITPP and tend to correlate with responses and survival after chemotherapy.
- 21 June 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-12
Open AccessPhase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors
Hypoxia is prominent in solid tumors and a recognized driver of malignancy. Thus far, targeting tumor hypoxia has remained unsuccessful. Myo-inositol trispyrophosphate (ITPP) is a re-oxygenating compound without apparent toxicity. In preclinical models, ITPP potentiates the efficacy of subsequent chemotherapy through vascular normalization. Here, we report the results of an unrandomized, open-labeled, 3 + 3 dose-escalation phase Ib study (NCT02528526) including 28 patients with advanced primary hepatopancreatobiliary malignancies and liver metastases of colorectal cancer receiving nine 8h-infusions of ITPP over three weeks across eight dose levels (1'866-14'500 mg/m2/dose), followed by standard chemotherapy. Primary objectives are assessment of the safety and tolerability and establishment of the maximum tolerated dose, while secondary objectives include assessment of pharmacokinetics, antitumor activity via radiological evaluation and assessment of circulatory tumor-specific and angiogenic markers. The maximum tolerated dose is 12,390 mg/m2, and ITPP treatment results in 32 treatment-related toxicities (mostly hypercalcemia) that require little or no intervention. 52% of patients have morphological disease stabilization under ITPP monotherapy. Following subsequent chemotherapy, 10% show partial responses while 60% have stable disease. Decreases in angiogenic markers are noted in ∼60% of patients after ITPP and tend to correlate with responses and survival after chemotherapy.